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Abstract
The capsid protein of human immunodeficiency virus type 1 was observed to undergo proteolytic cleavage in vitro when viral lysate was
incubated in the presence of dithiothreitol at acidic pH. Purified HIV-1 capsid protein was also found to be a substrate of the viral proteinase
in a pH-dependent manner; acidic pH (7) was necessary for cleavage, and decreasing the pH toward 4 increased the degree of processing.
Based on N-terminal sequencing of the cleavage products, the capsid protein was found to be cleaved at two sites, between residues 77 and
78 as well as between residues 189 and 190. Oligopeptides representing these cleavage sites were also cleaved at the expected peptide bonds.
The presence of cyclophilin A decreased the degree of capsid protein processing. Unlike the capsid protein, integrase was found to be
resistant toward proteolysis in good agreement with its presence in the preintegration complex.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
The retroviral proteinase (PR) plays a crucial role in the
late phase of the retroviral life cycle by processing of the
Gag and Gag-Pol polyproteins at the boundaries of the
functional domains, during viral assembly and maturation
(for a review see Oroszlan and Luftig, 1990). The retroviral
PR is a primary target for chemotherapy of AIDS patients,
and its inhibitors have been found to have beneficial values
in treatment (for a review see Eron, 2000). It was demon-
strated for equine infectious anemia virus (EIAV) (Roberts
et al., 1991a) and later for HIV (Welker et al., 2000) that the
PR is part of the core structure, which enters the infected
cells. Besides the PR, the core of HIV-1 also contains capsid
(CA), nucleocapsid (NC), reverse transcriptase (RT), RNase
H, integrase (IN), Vpr, and Nef (Welker et al., 2000).
During in vitro incubation of EIAV capsids, the NC was
further processed into smaller fragments by the incorporated
PR (Roberts and Oroszlan, 1989, Roberts et al., 1991a).
Later the HIV-1 NC was found to be processed in a similar
manner by HIV-1 PR (Wondrak et al., 1994). Among the
other proteins of the core, the HIV-1 RT, RNAse H, and Nef
have been demonstrated to be substrate of the HIV-1 PR
(Tomasselli et al., 1993, Welker et al., 1996, 2000). Fur-
thermore, the PR itself undergoes self-degradation (Mildner
et al., 1994), while Vpr remains intact in the capsid (Welker
et al., 2000) and it was found to be a nucleocytoplasmic
shuttling protein of the preintegration complex (Sherman et
al., 2001). Besides the viral components, cellular proteins
were also detected in virions, including the cellular peptidyl
prolyl isomerase, cyclophilin A (Cyp A), which is incorpo-
rated into the virion by binding to CA and which enhances
viral infectivity (Franke et al., 1994, Thali et al., 1994). The
precise function of Cyp A in HIV-1 replication is unknown.
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Cyp A appears to act on viral core disassembly
(Steinkasserer et al., 1995, Braaten et al., 1996). Here we
report whether the two remaining viral proteins of the core,
CA and IN, are substrates of HIV-1 PR. The CA was found
to be processed by the proteinase in a pH-dependent man-
ner; however, integrase was resistant toward PR-mediated
degradation. Since Cyp A binds to CA in virion, and alters
its conformation (Dietrich et al., 2001), we have also tested
the effect of Cyp A in CA processing.
Results
Capsid protein is a pH-dependent substrate of HIV-1 PR,
in vitro
Capsid protein (p24CA) purified from eukaryotic cells
infected with HIV-1 was incubated overnight with purified
recombinant HIV-1 PR in buffers at various pH (Fig. 1).
While no cleavage was observed at pH 7.0, decreasing the
pH resulted in substantial processing of the p24CA protein:
at pH 5.0 the largest, 22-kDa fragment appeared with very
low molecular weight fragments, while at pH 4.0, three
intermediate-sized bands also appeared (Fig. 1), implying
that the cleavage yielding these fragments may have a lower
pH optimum than the cleavage producing the 22 kDa and
the very short fragments.
Isolated virus from AD293T cells infected with HIV-
1HXB2 was disrupted by the addition of detergent (Triton
X-100) and was also incubated overnight at pH 4.0 (Fig. 1).
A substantial amount of the 24-kDa band disappeared,
yielding cleavage products whose mobility was identical to
the mobility of fragments observed with p24CA. To verify
that the cleaved protein of the viral lysate was the p24CA
capsid protein, N-terminal sequence of the 24-kDa band as
well as of the largest, 22-kDa cleavage product was deter-
mined, and both were found to be PIVQN-, the N-terminal
sequence of p24CA. This result also suggested that the cleav-
age yielding the largest, 22-kDa cleavage product occurred
at the C-terminal part of the protein. Addition of the specific
retroviral proteinase inhibitor UK 88,947 (Baboonian et al.,
1991) before incubation prevented the loss of the p24CA
protein in the viral lysate, suggesting that it was degraded by
the retroviral PR, incorporated into the virion (data not
shown).
Time-dependent processing of recombinant capsid protein
by HIV-1 PR
To determine the cleavage sites in the capsid protein,
recombinant p24CA protein expressed in Escherichia coli
(r-p24CA) was subjected to proteolysis by HIV-1 PR. At
1:20 PR:capsid ratio and pH 5.5 (which is optimal for the
PR) a time-dependent processing was observed, which was
prevented by the addition of 0.2 M ritonavir, a specific PR
inhibitor (Fig. 2). To identify all of the fragments obtained
from p24CA degradation, the cleavage products were sepa-
rated by SDS–polyacrylamide gel electrophoresis and trans-
ferred to a PVDF membrane; then Coomassie-stained bands
were cut out and subjected to N-terminal analysis (not
shown). Bands were identified by their N-terminal sequence
and by their apparent molecular weight (Table 1). Based on
these data, two cleavage sites were identified in the p24CA
protein, one between Ala 77 and Ala 78 of the N-terminal
domain of CA, and the other between Leu 189 and Leu 190
of the C-terminal domain of CA.
Effect of cyclophilin A on the processing of capsid protein
by HIV-1 PR
To study the effect of cyclophilin on the p24CA degra-
dation, r-p24CA was preincubated with cyclophilin A at pH
4.0 (which is optimal for the N-terminal site cleavage)
before addition of the PR into the reaction mixture. Binding
of Cyp A to p24CA substantially reduced the rate of cleav-
age of capsid protein (Fig. 3), indicating that this chaperone
was able to delay the proteolytic processing of CA by
HIV-1 PR. Serum albumin or lysozyme used in the same
concentration as Cyp A did not inhibit the cleavage of
p24CA, indicating that the effect of Cyp A was due to
specific protein–protein interaction.
Fig. 1. pH-dependent processing of viral p24CA by HIV-1 PR. The p24CA
protein purified from virus infected cells was incubated for 16 h at 37°C in
0.1 M Na-phosphate buffer containing 2.5 mM DTT at the indicated pH
with HIV-1 PR. Isolated HIV-1HXB2 was disrupted by the addition of 0.1%
Triton X-100 and 10 mM DTT and analyzed by SDS–polyacrylamide gel
electrophoreses without incubation or after 16 h incubation at 37°C. M
denotes the molecular weight marker. The full-size p24CA as well as the
observed major cleavage products are indicated by arrows.
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Cleavage of oligopeptides representing the processing
sites in the capsid protein by HIV-1 PR
Oligopeptides were synthesized, representing the cleav-
age sites at the identified sites in CA of HIV-1HXB2, and
assayed as substrates of HIV-1 PR. At assay conditions we
previously found to be optimal for HIV-1 PR (pH 5.6, 2 M
NaCl) (To¨zse´r et al., 1991), the peptide representing the
C-terminal cleavage site appeared to be a somewhat better
substrate (Table 2). When the kinetic parameters were de-
termined under conditions similar to that of the in vitro
protein cleavages at pH 4.0, the other substrate was much
better hydrolyzed (Table 2).
Integrase is not a substrate of HIV-1 PR
Recombinant IN of HIV-1 was incubated with HIV-1 PR
under the same conditions as used for the capsid cleavage.
During the 4 h incubation, the integrase protein remained
intact (Fig. 4).
Discussion
We have identified two cleavage sites in the HIV-1
p24CA, between residues 77 and 78 as well as between
residues 189 and 190. The cleavage was strongly pH-de-
pendent. No processing was observed at pH 7.2, decreas-
ing the pH to 6 already yielded a detectable level of
p24CA cleavage at the C-terminal domain, while the cleav-
age of the N-terminal domain was observed only at lower
pH. Oligopeptides representing these cleavage sites were
also cleaved at the expected peptide bonds. On the other
hand, integrase was found to be resistant toward proteolysis,
in good agreement with its presence in the preintegration
complex.
Based on the crystal structures of p24CA, the cleavage
site of the C-terminal domain is in helix 9, where Leu 189
is a part of the dimer interface (Berthet-Colominas et al.,
1999), while the cleavage site of the N-terminal domain is
in helix 4, which leads to the Cyp A binding loop (Berthet-
Colominas et al., 1999). These structural elements are in-
Fig. 2. Incubation of recombinant p24CA with HIV-1 proteinase. Recombinant p24CA was incubated with HIV-1 PR for the 0 (lane 1), 30 min (lane 2), 60
min (lane 3), 120 min (lane 4), and 240 min (lane 5) or for 240 min in the presence of a specific PR inhibitor, ritonavir (lane 6), and analyzed by SDS–PAGE.
M denotes the molecular weight marker. FR4 migrates higher than in the case of viral capsid protein (Table 1) owing to the presence of the N-terminal 6-his
tag.
Table 1
Analysis of full size p24CA (from HIVIIIB) and its fragments separated by SDS–polyacrylamide gel electrophoresis
Band Residues N-terminal sequence
of the protein
Molecular weight (kDa)
Observed Calculated
p24 1–231 P-I-V-Q-N- 26.0 25.6
FR1 1–189 P-I-V-Q-N- 22.0 21.3
FR2 78–231 A-E-X-D-R- 18.0 17.2
FR3 78–189 A-E-X-D-R- 13.0 12.9
PR (HIV-1 PR) P-Q-V-T-L- 11.0 10.8
FR4 1–77 Not determined 7.0 8.4
FR5 190–231 L-V-Q-N-A- 5.0 4.3
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compatible with the structural requirement for the PR-me-
diated hydrolysis, since the substrate should bind into the
enzyme in an extended conformation (for a review, see
Wlodawer and Erickson, 1993). Similar discrepancies were
also found with other protein substrates of HIV-1, in which
the cleavage site regions were found to be part of alpha
helices (Tomasselli and Heinrickson, 1994). However, the
crystals for determination for the p24CA structure were
grown at pH 7.5, at which the protein appeared to be
resistant toward proteolysis. The structure and higher orga-
nization of p24CA is very sensitive to the pH; below 6.6 the
multimeric capsid forms disassemble into monomers, and
its structure assumes a “molten globule” state (Misselwitz et
al., 1995; Ehrlich et al., 2001) in which the local structure
around the cleavage sites may be altered to allow productive
binding to the PR.
HIV-1 PR cleaves the Gag and Gag-Pol proteins at
various positions during viral maturation. The amino acid
residues in the P4–P3 region of these sites, which are
recognized by the PR, are listed in Table 3. Most of these
sites contain hydrophobic residues at the P2–P2 region.
Although only one viral HIV-1 PR maturation cleavage site,
the CA2p2 site, contains charged residue at this region, a
P2 glutamate (Louis et al., 2000), this residue is highly
conserved in HIV-1 (Korber et al., 1998). The cleavage at
this site is accelerated by lower pH, and this was suggested
to play a regulatory role in the viral protein processing
(Pettit et al., 1994). While the sequence of the cleavage site
at the C-terminal domain of p24 fits well into the other Gag
and Gag-Pol sequences, the cleavage site in the N-terminal
domain of p24 contains Glu residue at both the P2 and the
P2 positions (Table 3). Crystallographic structures of
HIV-1 PR have been reported with inhibitors or products
having P2 Glu residues (Tong et al., 1993; Weber et al.,
1997). In these structures the P2 Glu showed two weak
hydrogen bond interactions with the amides of Asp 29 and
Asp 30 of the enzyme. The proximity of the Glu side chain
to the side chain of Asp 30 suggested that they share a
proton (Weber et al., 1997). The presence of glutamate at
P2 position of various cleavage sites was found to be
responsible for the pH effect (Boross et al., 1999). The
presence of two glutamates in this p24 cleavage site may
enhance such a pH effect, explaining why lowering the pH
substantially enhanced the cleavage in the N-terminal do-
Fig. 3. Effect of cyclophilin A on HIV-1 PR-catalyzed processing of
p24CA. Recombinant p24CA protein alone (lanes 1 and 2) or complexed
with Cyp A (lanes 3 and 4) was incubated with (lanes 2 and 4) or without
HIV-1 PR (lanes 1 and 3) for 30 min at 37°C; then the reaction mixture was
analyzed by SDS–PAGE. M denotes the molecular weight marker.
Table 2
Cleavage of oligopeptides representing the cleavage sites within p24CA protein of HIVHXB2 by HIV-1 proteinase
Peptidea Assay
conditionsb
Km (mM) kcat (s1) kcat/Km
(mM1 s1)
1. INEEA-2-AEWDR A 0.617 0.035 0.20 0.01 0.32
B 0.1 N.D. 7.6c
2. MTETL-2-LVENR A 0.224 0.049 0.14 0.01 0.61
B 0.731 0.110 0.43 0.05 0.59
a Scissile bond is marked by an arrow.
b A; measured in phosphate buffer, pH 5.6, containing 2 M NaCl; B, measured in phosphate buffer, pH 4.0 in the absence of salt.
c Increase of the substrate concentration above the apparent Km value resulted in a decrease of the measurable activity. Therefore the kcat/Km value was
determined in a competitive assay by using substrate 2.
Fig. 4. Incubation of and p32IN HIV-1 integrase with HIV-1 proteinase.
Recombinant p32IN was incubated with (lane 1) or without (lane 2) HIV-1
PR for 4 h; then the reaction mixture was analyzed by SDS–PAGE. M
denotes the molecular weight marker.
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main of CA. Unlike the P2 and P2 glutamates, Glu at P3
and P3 in the peptide representing the cleavage site in the
C-terminal domain did not result in such an effect.
In the early phase of viral replication, the viral capsid
structure enters the cell. Based on compositional studies of
EIAV and HIV-1 capsids (Roberts et al., 1991b, Welker et
al., 2000), they contain the viral RNA covered by nucleo-
capsid protein, capsid protein, and at least the replication
enzymes (RT, RNaseH, IN, and PR). Reverse transcription
occurs in this highly organized structure; then a preintegra-
tion complex (PIC) is formed, containing the viral DNA as
well as integrase (Farnet and Haseltine, 1991), although
other proteins such as MA and Vpr were also detected in
PIC (Miller et al., 1997). So far the HIV-1 RT and RNase H
(Tomasselli et al., 1993), the NC protein (Wondrak et al.,
1994), and the PR itself (Mildner et al., 1994) were de-
scribed as substrate of the HIV-1 proteinase. Here we report
the CA protein is also a substrate of HIV-1 PR. Its process-
ing is strongly dependent from a pH-induced conforma-
tional change. Lowering the pH was also found to be re-
quired for the processing of RNaseH (Tomasselli et al.,
1993) and could remove the coordinated zinc from the NC
protein (Mely et al., 1996), which is a prerequisite of its
processing (Wondrak et al., 1994).
Although it has been shown previously that HIV-1 is
able to enter the cells by clathrin-coated vesicles (Grewe et
al., 1990), it has been demonstrated only recently that en-
docytic entry of HIV-1 into cells can lead to viral integra-
tion and gene expression (Fackler and Peterlin, 2000). In
fact, the vesicular pathway could be the predominant route
for certain virus isolates in infecting CD4 cells (Fackler
and Peterlin, 2000). Chloroquine, a weak base capable of
increasing the pH of acidic vesicles, was found to be able to
inhibit HIV-1 replication, by reducing the gp120 production
of the infected cells (Tsai et al., 1990). Chloroquine may
also block the early phase of replication of HIV-1 entering
the cell through receptor-mediated endocytosis.
Since the virus entering the cells contains the active
protease, its activity could be boosted by the acidic pH of
the endosomes, and protease-mediated cleavage of viral
proteins, including NC, and CA may be important for the
preparation of proper preintegration complex. The different
trafficking route of HIV-1 depending on the presence of
receptor and virus isolate (Fackler and Peterlin, 2000) may
be responsible at least in part for the conflicting results
obtained with PR inhibitors to study the role of PR in the
early phase of viral life cycle. Several research groups
including ours found an inhibitory effect on replication
(Baboonian et al., 1991; Nagy et al., 1994; Panther et al.,
1999; Goto et al., 2001), while others did not observe such
an effect (Jacobsen et al., 1992; Kaplan et al., 1996; Uchida
et al., 1997).
Materials and methods
Purification of the HIV-1 capsid protein
Purification of viral p24CA protein from cells infected
with HIV-1 was performed as described previously
(Veronese et al., 1988). For the expression of recombinant
capsid protein (r-p24CA), the plasmid bearing the CA pro-
tein from HIVIIIB isolate with an N-terminal 6-his tag was
obtained from Dr. Carol Carter (Department of Molecular
Genetics and Microbiology, S.U.N.Y. Stony Brook, USA).
Expression of the recombinant protein in BL21(DE3) E.
coli cells (Novagen) was induced by the addition of 0.4 mM
IPTG to the cultures and incubation at 37°C for 3 h. Bac-
terial cells were suspended in 10 mM Tris–HCl, pH 8.0
containing 150 mM NaCl, and 1 mM PMSF, and then
disrupted by sonication. The insoluble fraction was col-
lected by centrifugation and resuspended in 20 mM phos-
phate buffer, pH 7.5, containing 500 mM NaCl, 0.1% Triton
X-100, and 8 M urea. After sonication, the solution was
clarified by filtration and then applied to the Ni-NTA Su-
perflow affinity resin (Qiagen) equilibrated with the same
buffer. After extensive consecutive washing with a buffer
having the same composition as the loading buffer, but with
pH 6.0 and containing 500 mM LiCl, the recombinant
protein bound to the resin was eluted with 50 mM Na-
acetate, pH 5.0, containing 8 M urea, 500 mM NaCl, 10%
glycerol, 1% Triton X-100, and 5 mM -mercaptoethanol.
The purified protein was dialyzed overnight at 4°C, against
25 mM formic acid, lyophilized, and reconstituted in assay
buffer. Protein concentrations were determined by the Brad-
ford spectrophotometric method (Bio-Rad).
Purification of HIV-1 integrase
HIV-1 pINSD.His.Sol plasmid coding for a soluble in-
tegrase mutant (Jenkins et al., 1996) was obtained through
Table 3
Comparison of the HIV-1 Gag and Gag-Pol sites cleaved by the HIV-1
PR during maturation with the cleavage sites within p24CA protein of
HIVHXB2
Site of cleavage P4 P3 P2 P1 P1 P2 P3
MA2CA Ser-Gln-Asn-Tyr-2-Pro-Ile-Vala
CA2p2 Ala-Arg-Val-Leu-2-Ala-Glu-Ala
p22NC Ala-Thr-Ile-Met-2-Met-Gln-Arg
NC2p1 Arg-Gln-Ala-Asn-2-Phe-Leu-Gly
p12p6 Pro-Gly-Asn-Phe-2-Leu-Gln-Ser
in p6 Lys-Glu-Leu-Tyr-2-Pro-Leu-Thr
TFP2p6pol Asp-Leu-Ala-Phe-2-Leu-Gln-Gly
p6pol2PR Ser-Phe-Asn-Phe-2-Pro-Gln-Val
PR2RT Thr-Leu-Asn-Phe-2-Pro-Ile-Ser
p662p51 Ala-Glu-Thr-Phe-2-Tyr-Val-Asp
RT2IN Arg-Lys-Val-Leu-2-Phe-Leu-Asp
In CA (1) Asn-Glu-Glu-Ala-2-Ala-Glu-Trp
In CA (2) Thr-Glu-Thr-Leu-2-Leu-Val-Glu
a Cleavage site sequences are given as in Louis et al. (2000), but for the
HXB2 isolate. TFP, transframe protein, p66 and p51, are the two forms of
the RT subunits in the functional dimer.
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the AIDS Research and Reference Program. Integrase was
expressed in BL21(DE3) E. coli cells by addition of 0.4 mM
IPTG to the culture and incubation at 37°C for 3 h. Bacterial
cells were suspended in 10 mM Tris–HCl, pH 8.0 contain-
ing 150 mM NaCl, 0.1% Triton X-100, and treated with 100
g/ml DNAse I (Sigma) for 30 min at 37°C in the presence
of 10 mM MgCl2. The insoluble fraction was collected by
centrifugation and solubilized in 20 mM phosphate buffer,
pH 7.5, containing 500 mM NaCl, 0.1% Triton X-100, and
8 M urea. The solution was clarified by filtration and applied
to nickel-charged ProBond resin (Invitrogen) equilibrated
with the same buffer. After extensive consecutive washings
with the loading buffer, protein was eluted by gradually
decreasing the pH to 5.0. Fractions containing the recom-
binant protein (as determined by SDS–PAGE) were com-
bined and dialyzed overnight at 4°C, against 25 mM formic
acid, lyophilized, and reconstituted in assay buffer.
Virus production and in vitro capsid protein processing in
virus lysate
pMM4XB2 plasmid containing an infectious proviral
clone of HIV-1HXB2 was a kind gift of Dr. Ronald Swan-
strom (Department of Biochemistry and Biophysics, UNC
Lineberger Comprehensive Cancer Center, University of
North Carolina at Chapel Hill, NC). The plasmid (6 g) was
transfected onto 80% confluent AD293T cell monolayers in
a 9-cm petri dish by the calcium-phosphate method (Gra-
ham and van der Eb, 1973). Cells were maintained in
DMEM containing 10% fetal calf serum. Supernatant con-
taining virus particles was collected after 4 days, filtered
through a 0.45-m filter (Millipore), and purified by cen-
trifugation through a 20% sucrose pad. Viral pellet was
resuspended in 0.1% Triton X-100 containing 10 mM di-
thiothreitol. The pH of the disrupted virus solution was 4.0.
The p24 content of the viral lysate was measured according
to Popovic et al. (1984). An aliquot of the disrupted virus
was incubated for 16 h at 37°C in the presence or absence
of 50 M HIV-1 proteinase inhibitor UK 88,947 (Baboon-
ian et al., 1991). Ten to twelve micrograms of viral p24
were used per lane for SDS–PAGE.
Incubation of viral CA and IN proteins by HIV-1
proteinase
To determine the effect of pH on capsid protein degra-
dation, p24CA isolated from virus-infected cells (4.3 M
final concentration) was incubated in 100 mM potassium
phosphate, 2.5 mM DTT, pH 4.0 with recombinant HIV-1
PR (0.7 M final concentration) (Louis et al., 1991). After
16 h incubation reactions were stopped by the addition of
equal volume of 2 tricine–SDS sample buffer (Novex).
The samples were analyzed using 16 or 10–20% gradient
SDS–polyacrylamide tricine-buffered gel (Novex). Molec-
ular weight of the fragments was estimated using Rainbow
molecular weight markers (Amersham).
For the cleavage of r-p24CA as well as r-p32IN, recom-
binant protein (20 and 8 M final concentration, respec-
tively) was incubated with recombinant HIV-1 PR (1 M
final concentration) in 100 mM sodium acetate buffer, pH
5.5, containing 1 mM DTT, 1 mM EDTA, and 150 mM
NaCl. To test the effect of cyclophilin A on the capsid
cleavage, 43 M Cyp A (Sigma) was preincubated with the
capsid protein for 1 h at room temperature. As nonspecific
controls, bovine serum albumin and lysozyme (both from
Sigma) were used in 43 M concentration, in the same way
as Cyp A. After incubation for various times at 37°C,
reactions were stopped by the addition of an equal volume
of 2 tricine–SDS sample buffer, and the samples were
analyzed using 16 or 10–20% gradient SDS–polyacryl-
amide tricine-buffered gels (Novex).
Protein sequencing
Fragments of the CA protein cleaved by PR were sepa-
rated by SDS–PAGE and transferred to PVDF membrane
(ProBlot, Applied Biosystems) according to Towbin et al.,
(1979). N-terminal amino acid sequence analysis was car-
ried out by stepwise Edman degradation in a model 470A
gas-phase sequencer (Applied Biosystems) or in a model
910 protein sequencer (Knauer).
Oligopeptide synthesis and characterization
Oligopeptides were synthesized by solid-phase peptide
synthesis on a model 430A automated peptide synthesizer
(Applied Biosystems) using 9-fluorenyl-methyloxycarbonyl
chemistry and were purified by reversed-phase HPLC.
Amino acid composition of the peptides was determined
with a Beckman 6300 amino acid analyzer. Stock solutions
and dilutions were made in distilled water, and the peptide
concentrations were determined by amino acid analysis.
Enzyme assay with synthetic peptide substrates
The assay was performed either in 0.1 M phosphate
buffer, pH 5.6, 2 M NaCl (Buffer A) or in 0.1 M phosphate
buffer, pH 4.0 (Buffer B), as described previously (To¨zse´r et
al., 1992; Ishima et al., 2001). Briefly, the reaction mixture
was incubated at 37°C for 1 h, and the reaction was stopped
by the addition of guanidine–HCl (6 M final concentration).
The solution was acidified by the addition of 1% trifluoro-
acetic acid (TFA), and an aliquot was injected onto a Nova-
Pak C18 reversed-phase HPLC column (3.9  150 mm).
Substrates and the cleavage products were separated using
an increasing water-acetonitrile gradient (0–100%) in the
presence of 0.05% TFA. Composition of the cleavage prod-
ucts was determined by amino acid analysis. Kinetic param-
eters were determined at less than 20% substrate turnover
by fitting the data to the Michaelis–Menten equation by
using the Fig. P program (Fig. P Software Corp., Durham,
NC). The range of substrate concentration was 0.02–2.0
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mM, depending on the approximate Km values. Active-site
titration was performed for the HIV-1 PR with compound 3
in Grobelny et al. (1990).
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